The diffuse cutaneous systemic sclerosis market landscape is evolving from conventional symptom-focused strategies toward therapies that specifically target fibrosis and immune modulation, addressing ...

Sheffield Teaching Hospitals NHS Foundation Trust has become the only site in the UK to open a groundbreaking international trial which could revolutionise care for people living with a rare and ...

Vidofludimus calcium reduced the risk of confirmed disability worsening in people with progressive and relapsing forms of MS, ...

For decades, multiple sclerosis (MS) research has focused largely on the inflammatory lesions visible on MRI scans. Yet new ...

As they explained in their case report in the Journal of Neurology and Neuroscience, ophthalmologic examination identified ...

Treatment with Sanofi's frexalimab was seen in a study to safely maintain disease control over 2.5 years in adults with ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $42.0, a high estimate of $46.00, and a low estimate of $36.00. Observing a 5.0% ...

Allogene Therapeutics, Inc. ( NASDAQ: ALLO) Citi's SMID Call Series 2025 October 2, 2025 1:00 PM EDT ...

In a first-of-its-kind regional milestone, the Abu Dhabi Stem Cells Center (ADSCC), in collaboration with Yas Clinic Khalifa ...

Data at ECTRIMS will help back fenebrutinib as a potential addition to Roche’s arsenal of drugs, and help cement Ocrevus’s ...

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and irreversible lung disease associated with poor quality of ...